Telix Pharmaceuticals Limited
15.11.2017 02:01:36 CET | Globenewswire | Pressemeddelelse
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) ("Telix", the "Company"), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), has today listed on the Australian Securities Exchange (ASX) after raising $50 million in a fully underwritten Initial Public Offering (IPO).
Telix's issue price is $65c per share, with a market capitalization of $128 million, placing the IPO as the largest for the Australian ASX biotechnology sector, by capital raised, since 1994. The IPO was fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited.
The IPO has been strongly supported by existing shareholders, which includes both industry partners and domestic institutional investors such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Alium Capital Management and Allan Moss. Fidelity International is a cornerstone investor in the IPO at approximately 10% of the issued capital of the Company.
Telix Co-Founder and CEO Dr. Christian Behrenbruch, "We are delighted with the strong support from our partners, institutional and retail investors to make the IPO success We believe this is a very exciting opportunity for investors and we look forward to keeping shareholders closely informed of our progress as we develop our oncology product pipeline and engage with commercial partners."
Proceeds from the IPO will fund the development and completion of clinical trials for Telix's pipeline in renal (kidney), prostate and brain cancer (glioblastoma), and enable the Company to complete multiple clinical and product development milestones over the next 24 months.
Corporate Contact
Dr Christian Behrenbruch
CEO
Telix Pharmaceuticals Limited
Email: chris@telixpharma.com
Investor and Media Relations
Kyahn Williamson
WE Buchan
Tel: +61 (3) 9866 4722
Email: kwilliamson@buchanwe.com.au
WEB:http://www.telixpharma.com/
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Investeringsforeningen BankInvest21.4.2026 11:10:00 CEST | Pressemeddelelse
Investeringsforeningen BankInvest – Prospektopdatering
Kapitalforeningen BankInvest Select21.4.2026 11:10:00 CEST | Pressemeddelelse
Kapitalforeningen BankInvest Select – Prospektopdatering
Investeringsforeningen BankInvest21.4.2026 11:05:00 CEST | Pressemeddelelse
Forløb af ordinære generalforsamlinger i Investeringsforeningen BankInvest og Kapitalforeningen BankInvest Select
Kapitalforeningen BankInvest Select21.4.2026 11:05:00 CEST | Pressemeddelelse
Forløb af ordinære generalforsamlinger i Investeringsforeningen BankInvest og Kapitalforeningen BankInvest Select
Royal UNIBREW A/S21.4.2026 10:40:06 CEST | Press release
Q1 2026 trading statement
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
